Restoring Biological Harmony for Patients with Debilitating Disease

We are harnessing the power of microRNA science to develop therapies that normalize biological pathways and counterbalance disease.

Learn More

DEVELOPMENT PROGRAMS

Our pipeline is focused on serious diseases of high unmet need where the latest discoveries in microRNA biology are challenging traditional drug development paradigms and creating opportunities for novel therapeutic approaches.

Learn More

Recent Press Releases

July 10, 2018: miRagen Therapeutics Announces Initiation of Phase 2 Clinical Trial of MRG-201
June 4, 2018: Miragen Therapeutics to Present First Cobomarsen Phase 1 Clinical Trial Data From Patients With Adult T-Cell Leukemia/lymphoma and New Interim Data From Patients With Mycosis Fungoides at the 2018 American Society of Clinical Oncology Annual Meeting
May 31, 2018: miRagen Therapeutics to Present at Jefferies 2018 Global Healthcare Conference on Thursday, June 7th
May 16, 2018: miRagen Therapeutics to Present New Interim Data From Phase 1 Clinical Trial of Cobomarsen at the 2018 American Society of Clinical Oncology Annual Meeting
May 9, 2018: miRagen Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update

View All